SCHEMBL3829288

SCHEMBL3829288

CC(C)(Cc1ccncc1)OC(N)=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
NFKB1 P19838 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 2/20 0.43
PMP22 Q01453 1/20 0.43
NLRP3 Q96P20 1/20 0.43
FDPS P14324 1/20 0.42
RAB9A P51151 1/20 0.41
CYP17A1 P05093 2/20 0.40
PTPRB P23467 1/20 0.39
CYP19A1 P11511 5/20 0.38
GAA P10253 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3656311 0.82 SMN1; SMN2 (0.48) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27495164 0.82 CYP3A4 (0.50) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27504718 0.81 CYP1A2 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL29481079 0.81 CYP3A4 (0.69) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL29795260 0.81 CYP1A2 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL28272596 0.81 CYP3A4 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27586112 0.81 CYP3A4 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27915722 0.81 CYP3A4 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27495397 0.81 BLM (0.54) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1
SCHEMBL27734453 0.81 CYP3A4 (0.49) CYP3A4CYP1A2CYP2D6CYP2C9NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567497-B1 PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE PURDUE RESEARCH FOUNDATION (US) 2009-09-23 EP claimed
EP-3355925-B1 TREATMENT OF ACUTE TRAUMATIC INJURY UNIV ROCHESTER (US) 2024-02-28 EP disclosed
CN-110461848-A COMPOUNDS AND THEIR USE IN THE TREATMENT OF SCHISTOSOMIASIS MERCK PATENT GMBH 2019-11-15 CN disclosed
CN-1732154-B Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA 2010-09-08 CN disclosed
EP-1888584-A1 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY Brystol-Myers Squibb Company (US) 2008-02-20 EP disclosed
CN-1953747-A Diphenyl-indol-2-on compounds and their use in the treatment of cancer TOPOTARGET AS (DK) 2007-04-25 CN disclosed
WO-2006122137-A1 1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-16 WO disclosed
CN-1839133-A Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases AVANIR PHARMACEUTICALS (US) 2006-09-27 CN disclosed
CN-1732154-A Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM PHARMA (DE) 2006-02-08 CN disclosed
CN-1237060-C Quinzolone derivatives as alpha IA/B adrenergic receptor antagonists HOFFMANN LA ROCHE (CH) 2006-01-18 CN disclosed
CN-1484640-A Quinazolinone derivatives as alpha 1A/B adrenergic receptor antagonists - 2004-03-24 CN disclosed
CN-1420882-A Substd. oxoazaheterocyclyl compounds AVENTIS PHARM PROD INC (US) 2003-05-28 CN disclosed
CN-1333766-A Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds as factor xainhibitors AVENTIS PHARM PROD INC (US) 2002-01-30 CN disclosed